Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emma H Doud

Showing results (71-80 of 78) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 78 results.
Cell Reports|June 13, 2025
VDAC1 is a target for pharmacologically induced insulin hypersecretion in β cellsGitanjali Roy, Andrea Ordóñez, Derk D Binns, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
Drug DevelopmentKathryn A Haynes, Zackery A Cope, Sean-Paul Gerard Williams, et al.
ACS Measurement Science Au|August 28, 2024
Comprehensive Overview of Bottom-Up Proteomics Using Mass SpectrometryYuming Jiang, Devasahayam Arokia Balaya Rex, Dina Schuster, et al.
Pharmacological Research|February 4, 2024
New Ref-1/APE1 targeted inhibitors demonstrating improved potency for clinical applications in multiple cancer typesSilpa Gampala, Hye-Ran Moon, Randall Wireman, et al.
The Journal of Clinical Investigation|April 8, 2025
Alternative splicing of uromodulin enhances mitochondrial metabolism for adaptation to stress in kidney epithelial cellsAzuma Nanamatsu, George J Rhodes, Kaice A LaFavers, et al.
Biorxiv : the Preprint Server for Biology|August 6, 2025
Activation of PP2A-B56α leads to aberrant EGFR signaling and proliferative phenotypes in PDACClaire M Pfeffer, Sydney J Clifford, Saadia A Karim, et al.
Nature Medicine|October 6, 2015
Loss of BAP1 function leads to EZH2-dependent transformationLindsay M LaFave, Wendy Béguelin, Richard Koche, et al.
Nature Medicine|June 9, 2016
Reply to "Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status"Lindsay M LaFave, Wendy Béguelin, Richard Koche, et al.
Pageof 8

Showing results (71-80 of 78) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 78 results.
Cell Reports|June 13, 2025
VDAC1 is a target for pharmacologically induced insulin hypersecretion in β cellsGitanjali Roy, Andrea Ordóñez, Derk D Binns, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
Drug DevelopmentKathryn A Haynes, Zackery A Cope, Sean-Paul Gerard Williams, et al.
ACS Measurement Science Au|August 28, 2024
Comprehensive Overview of Bottom-Up Proteomics Using Mass SpectrometryYuming Jiang, Devasahayam Arokia Balaya Rex, Dina Schuster, et al.
Pharmacological Research|February 4, 2024
New Ref-1/APE1 targeted inhibitors demonstrating improved potency for clinical applications in multiple cancer typesSilpa Gampala, Hye-Ran Moon, Randall Wireman, et al.
The Journal of Clinical Investigation|April 8, 2025
Alternative splicing of uromodulin enhances mitochondrial metabolism for adaptation to stress in kidney epithelial cellsAzuma Nanamatsu, George J Rhodes, Kaice A LaFavers, et al.
Biorxiv : the Preprint Server for Biology|August 6, 2025
Activation of PP2A-B56α leads to aberrant EGFR signaling and proliferative phenotypes in PDACClaire M Pfeffer, Sydney J Clifford, Saadia A Karim, et al.
Nature Medicine|October 6, 2015
Loss of BAP1 function leads to EZH2-dependent transformationLindsay M LaFave, Wendy Béguelin, Richard Koche, et al.
Nature Medicine|June 9, 2016
Reply to "Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status"Lindsay M LaFave, Wendy Béguelin, Richard Koche, et al.
Pageof 8